Minimal residual disease-guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype.

Kislova M, Dmitrieva E, Naumova E, Pochtar M, Lugovskaya S, Kobzev Y, Loban A, Gladysheva M, Obukhova T, Biderman B, Sudarikov A, Volchkov E, Ivanova M, Ptushkin V, Visentin A, Nikitin E

Open source

DOI: 10.1111/bjh.70761
Published: 2026 Aug 19
Container: British journal of haematology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/bjh.70761,
  title = {Minimal residual disease-guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype.},
  author = {Kislova M and Dmitrieva E and Naumova E and Pochtar M and Lugovskaya S and Kobzev Y and Loban A and Gladysheva M and Obukhova T and Biderman B and Sudarikov A and Volchkov E and Ivanova M and Ptushkin V and Visentin A and Nikitin E},
  year = {2026},
  journal = {British journal of haematology},
  doi = {10.1111/bjh.70761},
  url = {https://doi.org/10.1111/bjh.70761}
}

RIS

TY  - JOUR
TI  - Minimal residual disease-guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype.
AU  - Kislova M
AU  - Dmitrieva E
AU  - Naumova E
AU  - Pochtar M
AU  - Lugovskaya S
AU  - Kobzev Y
AU  - Loban A
AU  - Gladysheva M
AU  - Obukhova T
AU  - Biderman B
AU  - Sudarikov A
AU  - Volchkov E
AU  - Ivanova M
AU  - Ptushkin V
AU  - Visentin A
AU  - Nikitin E
PY  - 2026
JO  - British journal of haematology
DO  - 10.1111/bjh.70761
UR  - https://doi.org/10.1111/bjh.70761
ER  -

APA

M, K., E, D., E, N., M, P., S, L., Y, K., A, L., M, G., T, O., B, B., A, S., E, V., M, I., V, P., A, V., & E, N. (2026). Minimal residual disease-guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype.. British journal of haematology. https://doi.org/10.1111/bjh.70761

Source records

pubmed · retrieved 2026-09-27T15:27:11.219Z